Cargando…

Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal

In the field of rare diseases (RDs), the evidence standard is often lower than that required by health technology assessment (HTA) and payer authorities. In this commentary, we propose that appropriate economic evaluation for rare disease treatments should be initially informed by cost-of-illness (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Armeni, Patrizio, Cavazza, Marianna, Xoxi, Entela, Taruscio, Domenica, Kodra, Yllka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908548/
https://www.ncbi.nlm.nih.gov/pubmed/33530652
http://dx.doi.org/10.3390/ijerph18031101